COVID-19:インドネシアのイベルメクチン分析結果:PROSPEROに掲載(動画):  Indonesian Meta-Analysis of Ivermectin:Find Efficacy Targeting COVID-19: 印度尼西亚研究人员对伊维菌素进行元分析:发现针对 COVID-19 的令人信服的功效

COVID-19:インドネシアのイベルメクチン分析結果:PROSPEROに掲載(動画): 
Indonesian Meta-Analysis of Ivermectin:Find Efficacy Targeting COVID-19:
印度尼西亚研究人员对伊维菌素进行元分析:发现针对 COVID-19 的令人信服的功效

ー英国PROSPEROに結果を掲載ー

インドネシアのペリタハラパン大学:

Tangerangが、メタアナリシスの実施結果を、ピアレビュー医学雑誌Reviewsin MedicalVirologyに掲載しました。

「イベルメクチン投与がCOVID-19患者の症状改善に効果的かどうか」という分析。

「PICO」フレームワークと呼ばれるもので実施。

以下の手法に準拠:

P:人数ーCovid-19人の患者数。
I:処方ーイベルメクチン薬;

C:比較対照群

イベルメクチンが投与されておらず、標準治療・対照/プラセボとし、て他の薬物療法のみを受けている患者のグループ。

O:結果

重度のCovid-19、死亡率、
陰性のRT-PCR検査結果率、
RT-PCR検査結果が陰性になるまでの時間、症状緩和率、
症状の緩和までの時間、
退院までの時間、

ランダム化臨床試験の記事も含まれていました。

Undertaking an extensive search in PubMed,
Europe PMC,
ClinicalTrials.gov,

the team assessed the quality of underlying studies using Jadad scale assessment, a tool for clinical trial studies.

Employing Review Manager 5.4 software for their statistical analysis,

the researchers reviewed 19 studies with 2,768 COVID-19 patients in the study.

They found that ivermectin was associated with a reduction in the severity of COVID-19,

reduction of mortality,
higher negative RT-PCR test result rate, shorter time to negative RT-PCR test results,
higher rate of reducing COVID symptoms,
shorter hospitalization duration as measured by time to discharge.

Yet another comprehensive meta-analysis

suggests ivermectin could offer beneficial effects when treating COVID-19.

Of course, the scholars recommend more clinical trials, as have all other researchers delving into the matter.

The Indonesia-based team

sought to provide some more clarity in the discussion about the efficacy of ivermectin,

clarifying whether they could find the evidence for ivermectin and its contribution to positive outcomes.

https://trialsitenews.com/indonesian-researchers-conduct-meta-analysis-of-ivermectin-find-compelling-efficacy-targeting-covid-19/